07:00 , Oct 27, 2014 |  BC Week In Review  |  Company News

Nuo Therapeutics sales and marketing update

Nuo Therapeutics (formerly Cytomedix Inc. ) re-launched its AutoloGel System in the U.S. under the Aurix System brand. The device produces topical platelet-rich plasma (PRP) gel from a patient's own blood and has been approved...
07:00 , Jun 30, 2014 |  BC Week In Review  |  Financial News

Cytomedix completes private placement of senior convertible notes

Cytomedix Inc. (OTCQX:CMXI), Gaithersburg, Md.   Business: Dermatology   Date completed: 2014-06-26   Type: Private placement of senior convertible notes   Raised: $26 million   Shares outstanding prior: 121.7 million   Investor: Deerfield Management  ...
07:00 , May 26, 2014 |  BC Week In Review  |  Clinical News

ALD-401: Phase II data

The double-blind, U.S. Phase II RECOVER-Stroke trial in patients with neurological damage arising from an ischemic stroke showed that an intracarotid infusion of 3 mL ALD-401 given 13-19 days post-stroke missed the primary endpoint of...
07:00 , Apr 7, 2014 |  BC Week In Review  |  Financial News

Cytomedix completes private placement of common stock and warrants

Cytomedix Inc. (OTCQX:CMXI), Gaithersburg, Md.   Business: Dermatology   Date completed: 3/31/14   Type: Private placement of common stock and warrants   Raised: $2 million   Shares: 3.8 million   Price: $0.52   Shares after...
07:00 , Apr 7, 2014 |  BC Week In Review  |  Company News

Cytomedix management update

Cytomedix Inc. (OTCQX:CMXI), Gaithersburg, Md.   Business: Dermatology   Hired: Dean Tozer as EVP and chief commercial officer, formerly VP of corporate development at the regenerative medicine unit of Shire plc  ...
07:00 , Apr 7, 2014 |  BC Week In Review  |  Financial News

Cytomedix completes private placement of senior convertible notes

Cytomedix Inc. (OTCQX:CMXI), Gaithersburg, Md.   Business: Dermatology   Date completed: 3/31/14   Type: Private placement of senior convertible notes   Raised: $9 million   Placement agent: BTIG   Shares outstanding prior: 114.6 million  ...
08:00 , Dec 16, 2013 |  BC Week In Review  |  Clinical News

AutoloGel System regulatory update

Cytomedix said the Centers for Medicare & Medicaid Services (CMS) issued final rules covering reimbursement for Cytomedix's AutoloGel System, which isolates and activates platelet-rich plasma (PRP) from a patient's own blood and is then used...
07:00 , Oct 7, 2013 |  BioCentury  |  Finance

3Q Stock Wrap-Up: Make it a double

For the second time this year, all market cap segments closed the quarter in the black. Large caps valued at $5 billion and above gained ground for the fifth consecutive quarter. They added 12%, and...
07:00 , Sep 23, 2013 |  BC Week In Review  |  Company News

Cytomedix dermatology news

Cytomedix will restructure R&D to reduce cash burn and focus on commercializing AutoloGel for chronic wound care. By year end, the company will "substantially" conclude its financial support of the Phase II RECOVER-Stroke trial with...
07:00 , Aug 19, 2013 |  BC Week In Review  |  Company News

Arthrex Inc., Cytomedix deal

Cytomedix granted orthopedic device company Arthrex exclusive, worldwide development and commercialization rights to Cytomedix's Angel Concentrated Platelet Rich Plasma System for five years, with a three year renewal option. Cytomedix received an upfront payment of...